GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Joinn Laboratories (China) Co Ltd (HKSE:06127) » Definitions » Capex-to-Revenue

Joinn Laboratories (China) Co (HKSE:06127) Capex-to-Revenue : 0.18 (As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Joinn Laboratories (China) Co Capex-to-Revenue?

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue.

Joinn Laboratories (China) Co's Capital Expenditure for the three months ended in Mar. 2024 was HK$-64.11 Mil. Its Revenue for the three months ended in Mar. 2024 was HK$352.84 Mil.

Hence, Joinn Laboratories (China) Co's Capex-to-Revenue for the three months ended in Mar. 2024 was 0.18.


Joinn Laboratories (China) Co Capex-to-Revenue Historical Data

The historical data trend for Joinn Laboratories (China) Co's Capex-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Joinn Laboratories (China) Co Capex-to-Revenue Chart

Joinn Laboratories (China) Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Capex-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.20 0.14 0.16 0.12 0.08

Joinn Laboratories (China) Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Capex-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.15 0.08 0.08 0.06 0.18

Competitive Comparison of Joinn Laboratories (China) Co's Capex-to-Revenue

For the Diagnostics & Research subindustry, Joinn Laboratories (China) Co's Capex-to-Revenue, along with its competitors' market caps and Capex-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Joinn Laboratories (China) Co's Capex-to-Revenue Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Joinn Laboratories (China) Co's Capex-to-Revenue distribution charts can be found below:

* The bar in red indicates where Joinn Laboratories (China) Co's Capex-to-Revenue falls into.



Joinn Laboratories (China) Co Capex-to-Revenue Calculation

Joinn Laboratories (China) Co's Capex-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (-210.794) / 2599.351
=0.08

Joinn Laboratories (China) Co's Capex-to-Revenue for the quarter that ended in Mar. 2024 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (-64.109) / 352.84
=0.18

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Joinn Laboratories (China) Co  (HKSE:06127) Capex-to-Revenue Explanation

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. The ratio shows how aggressively the company reinvests its revenue back into productive assets. However, a high ratio potentially indicates that the company has invested too much in innovation and infrastructure, taking up funds that could be used to boost productivity and increase revenue. Therefore, a high Capex to Revenue Ratio could be a positive or a negative sign depending on how effectively a company converts those investments into future earnings.


Joinn Laboratories (China) Co Capex-to-Revenue Related Terms

Thank you for viewing the detailed overview of Joinn Laboratories (China) Co's Capex-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Joinn Laboratories (China) Co (HKSE:06127) Business Description

Traded in Other Exchanges
Address
A5 Rongjing East Street, Beijing Economic-Technological Development Area, Beijing, CHN, 100176
Joinn Laboratories (China) Co Ltd is a non-clinical contract research organization(CRO) focused on drug safety assessment. It operates in three segments: Non-clinical studies services include drug safety assessment, drug metabolism & pharmacokinetics (DMPK) studies, & pharmacology & efficacy studies; Clinical trial & related services segment provides early-stage services such as clinical CRO services, co-managed phase I clinical research units, & bioanalytical services, and: Sales of research models engages in the design, production, breeding, & sales of research models, currently including non-human primates and rodents. The majority is from the Non- Clinical studies services. Its geographical segments are China, the United States, and Other countries, of which the majority is from China.

Joinn Laboratories (China) Co (HKSE:06127) Headlines

No Headlines